Active — Not RecruitingPhase 3

Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention

Turkey (Türkiye)100 participantsStarted 2013-01

Plain-language summary

The aim of this study is to evaluate the effects of N-acetyl cysteine on major cardiac and cerebral events in patients undergoing primary percutaneous coronary intervention who have moderate to high risk for contrast induced nephropathy. In a sub-group of patients coronary flow reserve will be evaluated.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with Acute ST Elevation Myocardial Infarction undergoing Primary Percutaneous Coronary intervention Who Have Moderate to High Risk For Contrast Induced Nephropathy (Mehran Score ≥5) Exclusion Criteria: * Patients \>18 years old with moderate to high risk for contrast induced nephropathy undergoing percutaneous coronary intervention * Low risk for contrast induced nephropathy (Mehran Score \<5) * Use of nephrotoxic agents (NSAIDs, aminoglycosides,recent contrast injection...) * Infection * Pregnancy, Lactation * Renal failure requiring dialysis * Hepatic failure * Allergy to NAC * History of Asthma * Chronic nitrate usage * Malignancy * Use of corticosteroids * Leucocytosis,Thrombocytosis,Anemia * Blood pressure of \>180/100mmHg despite anti-hypertensive therapy

What they're measuring

Major cardiac and cerebral events

Timeframe: 1 year

Trial details

NCT IDNCT01878344

SponsorSuleyman Demirel University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-01

View on ClinicalTrials.gov More Acute ST Segment Elevation Myocardial Infarction trials